Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

BIOLOGICAL3 trials

Sponsors

CanSino Biologics Inc.

Conditions

COVID-19

Phase 3

Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

WithdrawnNCT05124561

CanSino Biologics Inc.COVID-19

Start: 2021-12-15End: 2022-08-20Updated: 2023-06-18

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

TerminatedNCT05169008

CanSino Biologics Inc.COVID-19

Start: 2022-02-25End: 2023-01-13Updated: 2023-06-15

IH Convidecia as Second Booster Dose Against Breakthrough Infections

CompletedNCT05517642

CanSino Biologics Inc.COVID-19

Start: 2022-09-20End: 2023-05-02Updated: 2023-09-08

Related Papers

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.

2024-10-316 citations

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.

2022-05-20117 citations